This article has Open Peer Review reports available.
Osteoprotegerin secreted by inflammatory and invasive breast cancer cells induces aneuploidy, cell proliferation and angiogenesis
© Goswami and Sharma-walia. 2015
Accepted: 19 October 2015
Published: 25 November 2015
Osteoprotegerin (OPG) is a glycoprotein that has multifaceted role and is associated with several cancer malignancies like that of bladder carcinoma, gastric carcinoma, prostate cancer, multiple myeloma and breast cancer. Also OPG has been associated with several organ pathologies. The widespread expression of OPG suggests that OPG may have multiple biological activities that are yet to be explored.
The anchorage-independent sphere cultures of the adherent cells were instrumental in our study as it provided a deeper insight into the complexity of a 3D tumor. Cytokine profiling was performed for OPG’s detection in the microenvironment. ELISA and western blotting were performed to quantify the OPG secretion and measure the protein levels respectively. OPG expression was detected in human breast cancer tissue samples by IHC. To decipher OPG’s role in tumor aggressiveness both recombinant human OPG as well as OPG rich and depleted breast cancer cell conditioned media were tested. Western blotting and MTT assay were performed to detect changes in signaling pathways and proliferation that were induced in presence of OPG. Onset of aneuploidy, in presence of OPG, was measured by cell cycle analysis and western blotting. Finally, human Breast Cancer qBiomarker Copy Number PCR Array was used to detect how OPG remarkably induced gene copy numbers for oncogenic pathway regulators.
SUM149PT and SUM1315M02 cells secrete high levels of the cytokine OPG compared to primary human mammary epithelial cells (HMEC). High expression of OPG was also detected in human breast cancer tissue samples compared to the uninvolved tissue from the same patient. OPG induced proliferation of control HMEC spheres and triggered the onset of aneuploidy in HMEC sphere cultures. OPG induced the expression of aneuploidy related kinases Aurora-A Kinase (IAK-1), Bub1 and BubR1 probably through the receptor activator of nuclear factor kappa-B ligand (RANKL) and syndecan-1 receptors via the Erk, AKT and GSK3(3 signaling pathway. Gene copy numbers for oncogenic pathway regulators such AKT1, Aurora-A Kinase (AURKA or IAK-1), epidermal growth factor receptor (EGFR) and MYC with a reduction in the copy numbers of cyclin dependent kinase inhibitor 2A (CDKN2A), PTEN and DNA topoisomerase 2 alpha (TOP2A) were induced in presence of OPG.
These results highlight the role of OPG in reprogramming normal mammary epithelial cells to a tumorigenic state and suggest promising avenues for treating inflammatory breast cancer as well as highly invasive breast cancer with new therapeutic targets.
Breast cancer, the leading cause of death among women with an onset frequency of one in eight, is the most common type of cancer among women. However, despite the advancement in therapy, the mortality rate in breast cancer patients still remains high. The proactive, complex and dynamic tumor microenvironment of breast cancer adds to the grim scenario of the disease by accumulating inflammatory and angiogenic growth factors and creating a niche for the growth and metastasis of breast cancer cells.
The invasive carcinomas in humans can be highly metastasizing, less invasive or localized which indicate the dynamic and progressive nature of breast cancer. Studying the pathobiology of human breast cancer is challenging due to the inherent complexity. To investigate the pathobiology of human breast cancer successfully, it is necessary to maintain and recreate the characteristic three-dimensional (3D) architecture of the tissue in culture since conventional 2D monolayer has many limitations. 3D cultures more closely resemble the in vivo situation with regard to cell shape and its microenvironment . It is well established that the development and progression of a tumor toward the malignant phenotype is highly dependent on interactions between tumor cells and its microenvironment. The tumor microenvironment is made up of secreted growth and angiogenic factors, inflammatory cytokines, adhesion molecules, and circulating tumor cells. Tumor microenvironment promotes angiogenesis, cell migration, metastasis, and drives tumor progression to invasive carcinomas . Therefore, in the current study we performed cytokine profiling of breast cancer and healthy mammary cell conditioned media representing their microenvironment. We observed high levels of osteoprotegerin (OPG) secretion from the primary inflammatory ductal carcinoma SUM149PT cells and highly invasive ductal breast carcinoma SUM1315MO2 cells when compared to primary human mammary epithelial cells (HMEC).
OPG, also known as osteoclastogenesis inhibitory factor or tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), is expressed in many tissues such as heart, kidney, liver, spleen, and bone marrow . Besides being an important player in bone metabolism, OPG is a key regulator in vascular disease, prostate cancer, multiple myeloma, breast cancer, bladder carcinoma, and gastric carcinoma . There are multiple evidences suggesting OPG’s association to malignancy [4, 5]. OPG is a multifaceted molecule playing various functional role involved in cancer sustenance and progression such as tumor cell survival [4, 5] resistance to TRAIL induced apoptosis , angiogenesis and regulation of cellular phenotype . In this study, we aimed to examine the unexplored role(s) of OPG in aggressive breast cancer progression. We examined whether OPG rich secretions from aggressive breast cancer cells influence healthy HMECs and drive them towards tumorigenesis.
Our studies demonstrate that OPG induces proliferation, angiogenesis, aneuploidy and survival through manipulation of various survival and aneuploidy related kinases in HMEC spheres. Furthermore, OPG upregulated the expression of the cancer initiating cell marker CD24, in HMEC spheres. The biological significance of OPG was confirmed using recombinant human OPG, OPG rich or OPG depleted conditioned medium from breast cancer cells. Overall, our study reveals OPG as a potential therapeutic target for inflammation and invasion related aggressive breast cancer.
Breast cancer spheres are phenotypically different from the spheres cultured from normal mammary epithelial cells
To assess that the morphological changes are due to the microenvironmental factors, the primary spheres of SUM149PT and SUM1315MO2 were trypsinized and reseeded for the growth of secondary spheres and were observed after 10 days (Fig. 1d). Confocal microscopy was performed, which highlighted the adherence of multiple spheres forming bigger size spheres as observed previously (Fig. 1a). Also there was a change in morphology of spheres which can be attributed to the microenvironment that is enriched with various cytokines affecting the molecular and cellular genotype and phenotype.
Breast cancer adherent cells and spheres have unique a cytokine rich tumor microenvironment
Results of cytokine profiling (Additional file 1: Figure S1) clearly indicate the striking differences between the cytokine profile as well as the level of cytokine secretion between adherent cells and sphere cultures. These results demonstrate the probable complexity and difference in 3D sphere biology in comparison to 2D adherent cell biology. Since cytokine profiling is semi-quantitative, we therefore quantified the secretion of OPG by ELISA as described in the methods. Compared to HMEC, 500 and 1100 pg/ml of OPG was secreted in the conditioned media of SUM149PT and SUM1315MO2 cells, respectively (Fig. 2e). Western blot analysis also confirmed that the OPG level was significantly high in the adherent breast cancer cells when compared to HMEC cells (Fig. 2f. a).
To further validate the observation, Western blot analysis was performed in a different inflammatory breast cancer cell line SUM190PT which also revealed the high levels of OPG when compared to the HMEC cells (Fig. 2f. b).
OPG expression is significantly elevated in the breast cancer tissue
OPG induces in vitro tube formation in primary endothelial cells
OPG induces proliferation in HMEC spheres
OPG affects the CSCs population by downregulating the CD24 receptor expression
OPG induces onset of aneuploidy in normal HMEC spheres
OPG induces aneuploidy related kinases in normal HMEC spheres
To determine factors that may induce aneuploidy, we tested the basal levels of IAK-1/Aurora A, Bub1, BubR1 and Mps1 aneuploidy kinases in HMEC and breast cancer spheres (Fig. 8c). IAK-1/Aurora A, Bub1, BubR1 and Mps1 aneuploid kinase levels were upregulated in breast cancer spheres when compared to HMEC spheres (Fig. 8c). To further verify our results, we evaluated the status of aneuploidy kinases such as IAK-1/Aurora A, Bub1 and BubR1 (Fig. 8d and e) in HMEC spheres grown in different media combinations as indicated. The expression of IAK-1/Aurora A, Bub1, and BubR1 were upregulated in the HMEC spheres grown in OPG rich breast cancer cell conditioned media and recombinant human OPG (Fig. 8d and e). These results complemented the cell cycle results further strengthening the role of OPG in affecting the genomic integrity of normal healthy HMEC cells.
OPG induces survival and proliferation kinases in HMEC spheres
Long term culturing of HMEC spheres in OPG rich medium amplified genes relevant to oncogenic pathways
In order to understand these copy number variation in the context of inflammatory breast cancer, we profiled the copy number variation observed in inflammatory breast cancer tissue (Fig. 10d). We observed the upregulation of copy number of AKT1, AURKA, CDK4, EGFR, FGFR1, MYC, and PAK1 and downregulation of few tumor suppressors (PTEN, RB1, and PTEN) and cell cycle regulator CDKN2A (Fig. 10d).
Breast cancer heterogeneity and complexity occurs as a consequence of the dysregulation of numerous oncogenic pathways as well as many non-genetic factors, including tumor-microenvironment stresses including hypoxia, lactic acidosis, glucose deprivation, and cytokine rich microenvironment . Non-genetic factors of tumor microenvironment/paracrine milieu have been shown to integrate and influence the genetic framework of cancer; therefore we asked if continuous insult from OPG rich microenvironment could drive normal mammary epithelial cells (HMEC) towards tumorigenic. DNA copy number analysis of the HMEC spheres cultured for three generations (Fig. 10a) in OPG containing medium selectively amplified the DNA copy numbers of AKT1, AURK1, EGFR, MYC and PAK1 (Fig. 10e). There was appreciable amplification of the DNA copy numbers of CDK4 (Fig. 10e). DNA copy number profiling revealed remarkable reduction in the copy numbers of CDKN2A, PTEN and TOP2A in HMEC spheres cultured in presence of OPG (Fig. 10e). These results indicate that longer exposure of HMEC spheres to OPG rich microenvironment amplifies DNA copy number of tumorigenic genes (AKT1, AURK1, EGFR and MYC) and downregulates tumor suppressive genes (CDKN2A, PTEN and TOP2A).
Discussion and Conclusions
Breast cancer patients develop aggressive metastases to secondary organs such as bone marrow and bone [28–30]. Components of the tumor microenvironment, including macrophages, myoepithelial and endothelial cells, and several extracellular matrix (ECM) molecules, have been shown to play critical roles in mammary duct morphogenesis. Hence, the secretions from these cells, such as the cytokines in the of tumor microenvironment; are increasingly recognized as a major regulator of carcinogenesis and also a critical target for therapeutics . Our study highlights the importance of OPG in the breast cancer microenvironment and suggests how OPG has the tremendous capacity to drive normal healthy cells towards tumorigenesis.
The anchorage-independent sphere cultures of otherwise adherent cells were instrumental in our study as it provided a deeper insight into the complexity of a 3D tumor (Fig. 1). The differences in morphology and branching of breast cancer spheres indicated a very dynamic microenvironment and highlighted the complexity of the disease. We observed that the secretions from highly invasive breast cancer adherent and sphere cultures were rich in OPG (Additional file 1: Figure S1). Besides OPG, chemokines such as urokinase-type plasminogen activator receptor (uPAR), Oncostatin M (OSM), and GRO-α, which help in matrix-metalloprotease activation, ECM degradation, and facilitate metastasis, were also heavily secreted in the breast cancer microenvironment (Fig. 2). In addition, the increase in OPG secretion might be an indication that OPG, directly or indirectly, is inducing the secretion of many such oncogenic factors thus contributing to the severity of the disease.
OPG is associated with several organ pathologies such as endometriosis , periodontal , thyroid disease  and coronary heart disease [20, 35]. The widespread expression of OPG suggests that OPG may have multiple biological activities that are yet to be explored. Whether an OPG linked survival system operates in vivo remains to be established, but the elevated expression of OPG in tumors is reported to be associated with poor prognosis in gastric carcinoma . In our study, strong OPG expression was observed in inflammatory breast cancer tissues and moderate proportion of invasive ductal breast cancer tissues and this was absent from normal breast tissue. This observation supports the proposition that OPG expression might be universally involved in the severity of various kinds of breast cancer development and progression (Figs. 3 and 4).
Previous research has shown that OPG is actively involved in the tumor progression by aiding in angiogenesis  and OPG deficient mice exhibited vascular calcification thus highlighting the involvement of OPG in the active and intricate vascular system . Our in vitro studies demonstrate OPG involvement in endothelial tube formation in an in vitro model of angiogenesis which is in concordance with previous studies (Fig. 5).
Previous findings revealed OPG’s ability to attenuate TRAIL-induced apoptosis by activating integrin, focal adhesion kinase (FAK), and Akt signaling thus suggesting that OPG production may provide cells with a survival advantage . Similarly, our results showed that OPG induces proliferation and enhances survival of normal human mammary epithelial cells (Fig. 6). Hence it is possible that OPG upregulates the compensatory signaling mechanisms by binding to its signaling receptors thus mediating HMEC proliferation and increased survival.
CD24 is a marker for breast cancer initiating cell (] M. Al-Hajj, M.S. Wicha, A. Benito-Hernandez, S.J. Morrison, M.F. Clarke, Proceedings of the National Academy of Sciences of the United States of America 100 (7) (2003) 3983–3988) and modulating CD24 expression can influence the cell’s proliferating and metastasis capacity (P. Baumann, N. Cremers, F. Kroese, G. Orend, R. Chiquet-Ehrismann, T. Uede, H. Yagita, J.P. Sleeman, Cancer Research 65 (23) (2005) 10783–10793.) Previous studies have confirmed the CD24 enhanced proliferation and survival of cancer cells (] S.C. Smith, G. Oxford, Z. Wu, M.D. Nitz, M. Conaway, H.F. Frierson, G. Hampton, D. Theodorescu, Cancer Research 66 (4) (2006) 1917–1922). Here we show the CD24 upregulation in presence of OPG in control HMEC spheres (Fig. 7) thus supporting the increased proliferation and survival (Figs. 6 and 8) seen in the control HMEC spheres in presence of OPG.
Aneuploidy has been proposed to initiate tumorigenesis and is a remarkably common characteristic of tumor cells . Indeed, aneuploidy is found in precancerous lesions of the cervix [40, 41], head and neck , colon , oesophagus  and bone marrow . Aneuploidy has also been detected in premalignant breast  and skin  lesions in experimental animals as well. It has recently been confirmed that Aurora-A overexpression potentiates the oncogene activity of HRAS, not by interfering with the ploidy of the cell or the number of centrosomes but by influencing cell growth . Overexpression of other kinases like Bub1, BubR1, Mps1, and Aurora-B has been observed in a large variety of tumors containing polyploid cells with an abnormal number of centrosomes . Our study for the first time highlights the expression of aneuploid markers like IAK-1, Bub1, and BubR1 in the presence of OPG (Fig. 8). Our study is novel as it reveals OPG as one of the important factors in the breast cancer cell tumor microenvironment that can initiate the onset of aneuploidy in normal human mammary epithelial cells (Fig. 8). Furthermore, future investigations concentrating on the identification of the genetic defects that contribute in driving aneuploid kinases as oncogenes will help in targeting the aneuploid kinases for therapeutics.
Previous studies have reported that OPG induced cytoskeletal changes related to proliferation and migration of endothelial cells were associated with activation of Akt, Erk1/2, and Src . In our study, we found that OPG modulated the canonical survival and proliferation signaling pathways in the control HMEC spheres (Fig. 9). OPG activated Akt and GSK3β phosphorylation without notably affecting Erk1/2 activation (Fig. 9).
OPG has been reported to exert its effects via OPG receptors, such as type II membrane forms of RANKL [49, 50], TRAIL  and heparin sulfate containing proteoglycans, such as syndecan-1 [19, 52]. Syndecans are also recruiters of growth factors and metalloproteases  and their interactions are regulated by phosphorylation induced clustering and shedding of the extracellular domain [54–56]. The overexpression of syndecan-1 in adenocarcinoma cell lines has been shown to stimulate proliferation. The balance between shedding and phosphorylation induced clustering marks the switch to a proliferative and invasive phenotype [54–56]. Besides RANKL, TRAIL and syndecan-1, integrin mediated signaling has also been highlighted for activation of signaling pathways leading to cell migration and proliferation by OPG [48, 57]. Interestingly, immunoprecipitation of breast cancer cell extracts by OPG antibody revealed a major band at a molecular mass of 110 kDa (unpublished results). Mass spectrometry analysis revealed it to be nucleolin protein (unpublished results). Nucleolin is a multifunctional shuttling protein present in nucleus, cytoplasm, and on the surface of some types of cells . Nucleolin is a major constituent of nucleoli in exponentially growing cells  and functions in the organization of nucleolar chromatin , packaging of pre-rRNA , rDNA transcription , and ribosome assembly by shuttling between the nucleus and the cytoplasm . Expression of nucleolin on cell surface has been reported in HeLa cells , lymphoblastoid T cells , breast carcinoma cells [64, 65], lung , and laryngeal epithelial cells , and hepatocarcinoma cells . Nucleolin has also been reported to be expressed on the surface of endothelial cells in angiogenic blood vessels . Interaction between nucleolin and OPG in the breast cancer cells adds to another layer of complexity how OPG could be manipulating functions at the nuclear levels, and these studies are ongoing in our lab.
Since DNA copy number changes in cancer cells have prognostic impact [69–73], our studies have translational significance and need to be evaluated further using higher resolution methods. Aurora A kinase, EGFR, AKT/PI3K, MYC amplification and TOP2A gene copy number deletion or mutation has been significantly associated with several clinicopathological parameters and poor prognosis in breast cancer patients and are both a prognostic marker for poor outcome [71, 74, 75]. In our study, we found that OPG induced gene copy numbers for oncogenic pathway regulators such Aurora A, EGFR, AKT/PI3K, MYC (Fig. 10c). Aurora A is suggested to be one of the proliferation potency parameters which is an independent prognostic factor for early invasive breast cancer patients, and OPG long term exposure drastically induced the copy number of Aurora A kinase (Fig. 10c) further supporting our results in Fig. 8. Aurora kinases, centrosomal serine/threonine kinases, play an essential role in chromosome segregation, and their amplification and/or overexpression has been associated with centrosome anomalies and chromosomal instability as well as abrogation of DNA damage-induced apoptotic response and spindle assembly checkpoint override in tumor cells, thus Aurora A is also defined as an oncogene . Most importantly, the genes induced by OPG are oncogenic and are similar to the ones observed in inflammatory breast cancer patient tissue.
Primary human mammary epithelial cells (HMEC) (Cell Applications) were cultured in HMEC medium (Cell Applications). Primary inflammatory breast cancer SUM149PT and SUM190PT cells (Asterand), and highly invasive breast cancer SUM1315MO2 cells (Asterand) were grown in F-12 media (Gibco) supplemented with 10 % heat-inactivated fetal bovine serum (HyClone), insulin (Sigma), HEPES (Sigma), EGF (Sigma) for SUM1315MO2 and Hydrocortisone (Sigma) for SUM149PT as per instructions from Asterand. SUM190PT cells were grown in F-12 media (Gibco) supplemented with insulin (Sigma), HEPES (Sigma), Hydrocortisone (Sigma), Apo-Transferrin (Sigma), BSA (Sigma), ethanolamine (Sigma), sodium selenite (Sigma) and 2 % heat-inactivated fetal bovine serum (HyClone). Primary human microvascular dermal endothelial cells (HMVEC-d) (Lonza) were cultured in endothelial basal medium 2 (EBM-2) with growth factors (Lonza). All cells were tested for mycoplasma contamination by the standard Limulus assay (Charles River Endosafe) as per manufacturer’s instructions. All cells were cultured in LPS-free medium.
Antibodies against OPG, Bub1, BubR1 and Mps1 were from Abcam. P-GSK3β, GSK3β, P-p65, P65, AKT, P-AKT, P-p44/42, Erk2 and GAPDH antibodies were from Cell Signaling. Antibodies used against actin and tubulin were from Sigma. The antibody for IAK-1 was purchased from BD Biosciences. Recombinant human OPG from Abcam was dissolved in sterile PBS (pH7.4). For depletion of OPG from conditioned media, the anti-OPG antibody was from R&D Systems, Inc. Antibodies against CD44 and CD24 were purchased from BD Biosciences.
In vitro sphere culture
Spheres referred as to multicellular tumor spheroids were introduced to in vitro cell culture systems in the early 1970s . Cells were plated at a density of 106 cells/well in a 6-well (Corning) or 104 cells/well in 24-well (Corning) ultra-low attachment plates, grown for 7 days at 37 °C in a humidified atmosphere of 95 % air and 5 % CO2 to induce sphere formation. Spheres were collected by centrifugation after 8 days.
Sections from breast tissue samples of healthy subjects and patients were obtained from Biochain Institute, Inc. (breast tumor tissue array Z7020007). The tumor diagnosis and tumor grading (stages I-III) for the breast cancer tissue was done by Biochain Institute Inc. Inflammatory breast cancer tissue sample (breast tumor tissue array T22350862-2) was also obtained from Biochain as well. Permission has been obtained according to the Declaration of Helsinki and following the specific authorization of the local Institutional Review Board (IRB) Committee to which the Chicago Medical School, Rosalind Franklin University of Medicine and Science refers (Institutional Review Board; IRB protocol 383 MIC). Since the tissue sections were commercially obtained from the BioChain Institute, Inc company, each sample is anonymous and blinded for laboratory research use. IHC was performed using primary antibodies against human OPG or IgG control as described previously . Counterstaining was done by hematoxylin .
The conditioned media of adherent HMEC, SUM149PT and SUM1315MO2 cells were collected, centrifuged and OPG levels were measured in the supernatants were measured by ELISA (Raybiotech) according to the manufacturer’s instructions. Results are expressed as the amount of OPG secreted (pg/ml) per 106 cells.
The Proliferating Index of cells with metabolically active mitochondria was determined by the 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)–based colorimetric assay (ATCC) as described previously . Briefly, 4 × 104 HMEC cells were allowed to grow into spheres in the presence of HMEC complete growth medium, conditioned media from SUM149PT and SUM1315MO2, OPG depleted conditioned media of SUM149PT and SUM1315MO2 and HMEC media reconstituted with 500 pg/ml or 1100 pg/ml recombinant human OPG in 24 well ultra-low attachment plates for 8 days. 100 μl of MTT reagent was added to all the sphere cultures after 8 days and further incubated for 4 h for the development of insoluble purple precipitate. Purple precipitate was solubilized in detergent and then read at 562 nm. The amount of MTT (yellow tetrazolium salt) that is converted to insoluble purple formazan crystals represents the number of proliferating cells.
Cell cycle analysis by flow cytometry
HMEC spheres were grown in various media as previously described for cell proliferation assay . Harvested spheres were trypsinized, cells were diluted to 106 cells/ml and DNA distribution analysis was performed. Cells were fixed with 70 % methanol overnight and DNA was stained with propidium iodide (PI) at a final concentration of 50 mg/ml with RNaseA (100 U/ml) prior to flow cytometry analysis using LSRII (BD Biosciences). Results were analyzed using ModFit Lt V3 software (Verity Software House).
Stem cell analysis by flow cytometry
HMEC spheres were grown in various media as previously described for cell proliferation assay . Harvested spheres were trypsinized and cells were diluted to 106 cells/ml. Combinations of fluorochrome-conjugated monoclonal antibodies obtained from BD Biosciences (San Diego, CA, USA) against human CD44 (FITC) and CD24 (Alexa 647) or their respective isotype controls were added to the cell suspension at concentrations recommended by the manufacturer and incubated at 4 °C in the dark for 30 to 40 min. The labeled cells were washed in the wash buffer and DAPI was added to gate the live cells during the flow cytometry analysis using LSRII (BD Biosciences). Results were analyzed using ModFit Lt V3 software (Verity Software House).
In vitro capillary tube formation assay
HMEC, SUM149PT and SUM1315MO2 adherent cell conditioned media, OPG depleted SUM149PT and SUM1315MO2 conditioned media, and HMEC media reconstituted with 500 pg/ml or 1100 pg/ml recombinant human OPG were used for an in vitro capillary tube formation assay as per manufacturer’s instructions (BD Biosciences). Briefly, 104 HMVEC-d cells were plated on a matrigel coated 96-well plate with different media, incubated for 16 h in 5 % CO2 at 37 °C, and examined for capillary tube formation under an inverted microscope and photographed. The assay was done in duplicate and each experiment was repeated three times.
Western blot analysis
Cell or sphere protein lysates were quantitated by BCA assay. Equal amounts of protein (40 μg/lane) were separated on SDS-PAGE, electrotransferred to 0.45-mm nitrocellulose membranes, blocked with 5 % BSA, probed with antibodies of interest, and visualized using an enhanced-chemiluminescence (ECL) detection system.
Conditioned medium obtained from adherent and sphere cultures of HMEC, SUM149PT and SUM1315MO2 were spun at 1000 rpm for 10 min at 4 °C to remove the particulates and assayed for cytokine profiling using Raybiotech human cytokine antibody array AAH-CYT-7. The cytokine antibody array membranes were incubated with various conditioned media at 4 °C overnight. The membranes were washed, incubated with 1 ml of primary biotin-conjugated antibody at room temperature for 2 h, washed, incubated with 2 ml of horseradish peroxidase-conjugated streptavidin at room temperature for 45 min, and developed using ECL. Signal intensities were quantitated using an Alpha Inotech image analysis system. Signal intensities from all arrays were normalized to the same background levels with positive and negative controls using Raybiotech array AAH-CYT-7 analysis software.
Human breast cancer qBiomarker copy number profiling
HMEC cells were allowed to make spheres in the presence of recombinant human OPG rich medium. HMEC spheres were cultured for three generations, each generation being of 7 days. Breast cancer spheres were also generated from SUM149PT and SUM1315MO2 cells and cultured for three generations. At the end of the third generation, DNA prepared from these spheres was used to profile qBiomarker Copy Number using the human Breast Cancer qBiomarker Copy Number PCR Array from SABiosciences. Apart from spheres, genomic DNA was also isolated from the inflammatory breast cancer patient tissue sample for profiling qBiomarker Copy Number. This array profiles the copy number of 23 genes reported to undergo frequent genomic alterations in human breast tumor DNA. Genes were chosen from the most frequently amplified or deleted genes relevant to oncogenic pathways and breast cancer biology based on the primary literature and public databases. The array analyzed each gene in each sample in quadruplicate and includes a stable multi-copy reference assay for accurate copy number determination via appropriate DNA input normalization. qBiomarker Copy Number PCR Arrays are the most reliable and sensitive copy number profiling technology for analyzing a panel of loci in signal transduction pathways or disease related gene networks.
We thank Dr. Bala Chandran, Dr. Alice Gilman-Sachs and Keith Philibert for critically reading the manuscript. We gratefully acknowledge the help from Robert Dickinson (Flow cytometry core facility, RFUMS), and Patricia Loomis (Confocal microscopy core facility, RFUMS) for assisting with flow cytometry, and microscopic studies, respectively.
This study was supported by Rosalind Franklin University of Medicine and Science start-up funds and RFUMS-Advocate Lutheran General Hospital grant to NSW.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Kim JB, Stein R, O’Hare MJ. Three-dimensional in vitro tissue culture models of breast cancer-- a review. Breast Cancer Res Treat. 2004;85(3):281–91. Epub 2004/04/28.View ArticlePubMedGoogle Scholar
- Artacho-Cordon A, Artacho-Cordon F, Rios-Arrabal S, Calvente I, Nunez MI. Tumor microenvironment and breast cancer progression: a complex scenario. Cancer Biol Ther. 2012;13(1):14–24. Epub 2012/02/18.View ArticlePubMedGoogle Scholar
- Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 2006;12(1):17–25. Epub 2005/12/17.View ArticlePubMedGoogle Scholar
- Holen I, Shipman CM. Role of osteoprotegerin (OPG) in cancer. Clin Sci (Lond). 2006;110(3):279–91. Epub 2006/02/09.View ArticleGoogle Scholar
- Holen I, Cross SS, Neville-Webbe HL, Cross NA, Balasubramanian SP, Croucher PI, et al. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival? Breast Cancer Res Treat. 2005;92(3):207–15. Epub 2005/09/13.View ArticlePubMedGoogle Scholar
- De Toni EN, Thieme SE, Herbst A, Behrens A, Stieber P, Jung A, et al. OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer. Clin Cancer Res. 2008;14(15):4713–8. Epub 2008/08/05.Google Scholar
- Cross SS, Yang Z, Brown NJ, Balasubramanian SP, Evans CA, Woodward JK, et al. Osteoprotegerin (OPG)--a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int J Cancer. 2006;118(8):1901–8. Epub 2005/11/16.View ArticlePubMedGoogle Scholar
- Shipman CM, Croucher PI. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 2003;63(5):912–6. Epub 2003/03/05.PubMedGoogle Scholar
- Neville-Webbe HL, Cross NA, Eaton CL, Nyambo R, Evans CA, Coleman RE, et al. Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat. 2004;86(3):269–79. Epub 2004/11/30.View ArticlePubMedGoogle Scholar
- Holen I, Croucher PI, Hamdy FC, Eaton CL. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res. 2002;62(6):1619–23. Epub 2002/03/26.PubMedGoogle Scholar
- Daniel L, Lechevallier E, Bouvier C, Coulange C, Pellissier JF. Adult mesoblastic nephroma. Pathol Res Pract. 2000;196(2):135–9. Epub 2000/03/09.View ArticlePubMedGoogle Scholar
- Kristiansen G, Denkert C, Schluns K, Dahl E, Pilarsky C, Hauptmann S. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol. 2002;161(4):1215–21. Epub 2002/10/09.View ArticlePubMedPubMed CentralGoogle Scholar
- Jacob J, Bellach J, Grutzmann R, Alldinger I, Pilarsky C, Dietel M, et al. Expression of CD24 in adenocarcinomas of the pancreas correlates with higher tumor grades. Pancreatology. 2004;4(5):454–60. Epub 2004/07/17.View ArticlePubMedGoogle Scholar
- Fujikuni N, Yamamoto H, Tanabe K, Naito Y, Sakamoto N, Tanaka Y, et al. Hypoxia-mediated CD24 expression is correlated with gastric cancer aggressive-ness by promoting cell migration and invasion. Cancer Sci. 2014;105(11):1411–20. doi:10.1111/cas.12522. Epub 2014 Oct 18.View ArticlePubMedPubMed CentralGoogle Scholar
- Su N, Peng L, Xia B, Zhao Y, Xu A, Wang X, et al. Lyn is involved in CD24-induced ERK1/2 activation in colorectal cancer. Mol Cancer. 2012;26(11):43. doi:10.1186/1476-4598-11-43.View ArticleGoogle Scholar
- Weichert W, Denkert C, Burkhardt M, Gansukh T, Bellach J, Altevogt P, et al. Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res. 2005;11(18):6574-81.View ArticlePubMedGoogle Scholar
- Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer. 2005;5(10):773–85. Epub 2005/10/01.View ArticlePubMedGoogle Scholar
- Nigg EA. Centrosome aberrations: cause or consequence of cancer progression? Nat Rev Cancer. 2002;2(11):815–25. Epub 2002/11/05.View ArticlePubMedGoogle Scholar
- Yongchaitrakul T, Manokawinchoke J, Pavasant P. Osteoprotegerin induces osteopontin via syndecan-1 and phosphoinositol 3-kinase/Akt in human periodontal ligament cells. J Periodontal Res. 2009;44(6):776–83. Epub 2009/07/16.View ArticlePubMedGoogle Scholar
- Lawrie A, Waterman E, Southwood M, Evans D, Suntharalingam J, Francis S, et al. Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension. Am J Pathol. 2008;172(1):256–64. Epub 2007/12/25.View ArticlePubMedPubMed CentralGoogle Scholar
- Stranger BE, Forrest MS, Dunning M, Ingle CE, Beazley C, Thorne N, et al. Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science. 2007;315(5813):848–53. Epub 2007/02/10.View ArticlePubMedPubMed CentralGoogle Scholar
- Feuk L, Marshall CR, Wintle RF, Scherer SW. Structural variants: changing the landscape of chromosomes and design of disease studies. Hum Mol Genet. 2006;15 Spec No 1:R57–66. Epub 2006/05/03.View ArticlePubMedGoogle Scholar
- Conrad DF, Andrews TD, Carter NP, Hurles ME, Pritchard JK. A high-resolution survey of deletion polymorphism in the human genome. Nat Genet. 2006;38(1):75–81. Epub 2005/12/06.View ArticlePubMedGoogle Scholar
- Kleinjan DA, van Heyningen V. Long-range control of gene expression: emerging mechanisms and disruption in disease. Am J Hum Genet. 2005;76(1):8–32. Epub 2004/11/19.View ArticlePubMedGoogle Scholar
- Somerville MJ, Mervis CB, Young EJ, Seo EJ, del Campo M, Bamforth S, et al. Severe expressive-language delay related to duplication of the Williams-Beuren locus. N Engl J Med. 2005;353(16):1694–701. Epub 2005/10/21.View ArticlePubMedPubMed CentralGoogle Scholar
- Lee JA, Madrid RE, Sperle K, Ritterson CM, Hobson GM, Garbern J, et al. Spastic paraplegia type 2 associated with axonal neuropathy and apparent PLP1 position effect. Ann Neurol. 2006;59(2):398–403. Epub 2005/12/24.View ArticlePubMedGoogle Scholar
- Gatza ML, Kung HN, Blackwell KL, Dewhirst MW, Marks JR, Chi JT. Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes. Breast Cancer Res. 2011;13(3):R62. Epub 2011/06/16.View ArticlePubMedPubMed CentralGoogle Scholar
- Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94(2):153–6. Epub 2001/10/23.View ArticlePubMedGoogle Scholar
- Bhatia P, Sanders MM, Hansen MF. Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. Clin Cancer Res. 2005;11(1):162–5. Epub 2005/01/27.PubMedGoogle Scholar
- Patel A, Lefemine V, Yousuf SM, Abou-Samra W. Granular cell tumour of the pectoral muscle mimicking breast cancer. Cases J. 2008;1(1):142. Epub 2008/09/09.View ArticlePubMedPubMed CentralGoogle Scholar
- Place AE, Jin Huh S, Polyak K. The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res. 2011;13(6):227. Epub 2011/11/15.View ArticlePubMedPubMed CentralGoogle Scholar
- Doi S, Yorioka N, Masaki T, Ito T, Shigemoto K, Harada S. Increased serum osteoprotegerin level in older and diabetic hemodialysis patients. Ther Apher Dial. 2004;8(4):335–9. Epub 2004/07/28.View ArticlePubMedGoogle Scholar
- Liu D, Xu JK, Figliomeni L, Huang L, Pavlos NJ, Rogers M, et al. Expression of RANKL and OPG mRNA in periodontal disease: possible involvement in bone destruction. Int J Mol Med. 2003;11(1):17–21. Epub 2002/12/07.PubMedGoogle Scholar
- Hofbauer LC, Kluger S, Kuhne CA, Dunstan CR, Burchert A, Schoppet M, et al. Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland. J Cell Biochem. 2002;86(4):642–50. Epub 2002/09/05.View ArticlePubMedGoogle Scholar
- Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab. 2003;88(3):1024–8. Epub 2003/03/12.View ArticlePubMedGoogle Scholar
- Ito R, Nakayama H, Yoshida K, Kuraoka K, Motoshita J, Oda N, et al. Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma. Virchows Arch. 2003;443(2):146–51. Epub 2003/07/03.View ArticlePubMedGoogle Scholar
- Tintut Y, Abedin M, Cho J, Choe A, Lim J, Demer LL. Regulation of RANKL-induced osteoclastic differentiation by vascular cells. J Mol Cell Cardiol. 2005;39(2):389–93. Epub 2005/05/17.View ArticlePubMedGoogle Scholar
- Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998;273(23):14363–7. Epub 1998/06/11.View ArticlePubMedGoogle Scholar
- Weaver BA, Cleveland DW. Does aneuploidy cause cancer? Curr Opin Cell Biol. 2006;18(6):658–67. Epub 2006/10/19.View ArticlePubMedGoogle Scholar
- Munger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M, et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol. 2004;78(21):11451–60. Epub 2004/10/14.View ArticlePubMedPubMed CentralGoogle Scholar
- Ried T, Heselmeyer-Haddad K, Blegen H, Schrock E, Auer G. Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: a phenotype/genotype correlation. Genes Chromosomes Cancer. 1999;25(3):195–204. Epub 1999/06/24.View ArticlePubMedGoogle Scholar
- Ai H, Barrera JE, Meyers AD, Shroyer KR, Varella-Garcia M. Chromosomal aneuploidy precedes morphological changes and supports multifocality in head and neck lesions. Laryngoscope. 2001;111(10):1853–8. Epub 2002/01/22.View ArticlePubMedGoogle Scholar
- Doak SH, Jenkins GJ, Parry EM, Griffiths AP, Baxter JN, Parry JM. Differential expression of the MAD2, BUB1 and HSP27 genes in Barrett’s oesophagus-their association with aneuploidy and neoplastic progression. Mutat Res. 2004;547(1–2):133–44. Epub 2004/03/12.View ArticlePubMedGoogle Scholar
- Amiel A, Gronich N, Yukla M, Suliman S, Josef G, Gaber E, et al. Random aneuploidy in neoplastic and pre-neoplastic diseases, multiple myeloma, and monoclonal gammopathy. Cancer Genet Cytogenet. 2005;162(1):78–81. Epub 2005/09/15.View ArticlePubMedGoogle Scholar
- Medina D. Biological and molecular characteristics of the premalignant mouse mammary gland. Biochim Biophys Acta. 2002;1603(1):1–9. Epub 2002/09/21.PubMedGoogle Scholar
- Dooley TP, Mattern VL, Moore CM, Porter PA, Robinson ES, VandeBerg JL. Cell lines derived from ultraviolet radiation-induced benign melanocytic nevi in Monodelphis domestica exhibit cytogenetic aneuploidy. Cancer Genet Cytogenet. 1993;71(1):55–66. Epub 1993/11/01.View ArticlePubMedGoogle Scholar
- Tatsuka M, Sato S, Kitajima S, Suto S, Kawai H, Miyauchi M, et al. Overexpression of Aurora-A potentiates HRAS-mediated oncogenic transformation and is implicated in oral carcinogenesis. Oncogene. 2005;24(6):1122–7. Epub 2004/12/14.View ArticlePubMedGoogle Scholar
- Lane D, Matte I, Laplante C, Garde-Granger P, Rancourt C, Piche A. Osteoprotegerin (OPG) activates integrin, focal adhesion kinase (FAK), and Akt signaling in ovarian cancer cells to attenuate TRAIL-induced apoptosis. J Ovarian Res. 2013;6(1):82. Epub 2013/11/26.View ArticlePubMedPubMed CentralGoogle Scholar
- Hikita A, Tanaka S. Ectodomain shedding of receptor activator of NF-kappaB ligand. Adv Exp Med Biol. 2007;602:15–21. Epub 2007/10/31.View ArticlePubMedGoogle Scholar
- Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun. 2000;275(3):768–75. Epub 2000/09/07.View ArticlePubMedGoogle Scholar
- Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3(6):673–82. Epub 1995/12/01.View ArticlePubMedGoogle Scholar
- Mosheimer BA, Kaneider NC, Feistritzer C, Djanani AM, Sturn DH, Patsch JR, et al. Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. J Clin Endocrinol Metab. 2005;90(5):2964–71. Epub 2005/02/25.View ArticlePubMedGoogle Scholar
- Solecki DJ. Sticky situations: recent advances in control of cell adhesion during neuronal migration. Curr Opin Neurobiol. 2012;22(5):791–8. Epub 2012/05/09.View ArticlePubMedPubMed CentralGoogle Scholar
- Feistritzer C, Kaneider NC, Sturn DH, Wiedermann CJ. Syndecan-4-dependent migration of human eosinophils. Clin Exp Allergy. 2004;34(5):696–703. Epub 2004/05/18.View ArticlePubMedGoogle Scholar
- Melrose J, Isaacs MD, Smith SM, Hughes CE, Little CB, Caterson B, et al. Chondroitin sulphate and heparan sulphate sulphation motifs and their proteoglycans are involved in articular cartilage formation during human foetal knee joint development. Histochem Cell Biol. 2012;138(3):461–75. Epub 2012/05/24.View ArticlePubMedGoogle Scholar
- Pap T, Bertrand J. Syndecans in cartilage breakdown and synovial inflammation. Nat Rev Rheumatol. 2013;9(1):43–55. Epub 2012/10/24.View ArticlePubMedGoogle Scholar
- Kobayashi-Sakamoto M, Isogai E, Hirose K, Chiba I. Role of alphav integrin in osteoprotegerin-induced endothelial cell migration and proliferation. Microvasc Res. 2008;76(3):139–44. Epub 2008/07/29.View ArticlePubMedGoogle Scholar
- Srivastava M, Pollard HB. Molecular dissection of nucleolin’s role in growth and cell proliferation: new insights. FASEB J. 1999;13(14):1911–22. Epub 1999/11/02.PubMedGoogle Scholar
- Bugler B, Caizergues-Ferrer M, Bouche G, Bourbon H, Amalric F. Detection and localization of a class of proteins immunologically related to a 100-kDa nucleolar protein. Eur J Biochem. 1982;128(2–3):475–80. Epub 1982/11/15.PubMedGoogle Scholar
- Erard MS, Belenguer P, Caizergues-Ferrer M, Pantaloni A, Amalric F. A major nucleolar protein, nucleolin, induces chromatin decondensation by binding to histone H1. Eur J Biochem. 1988;175(3):525–30. Epub 1988/08/15.View ArticlePubMedGoogle Scholar
- Bugler B, Bourbon H, Lapeyre B, Wallace MO, Chang JH, Amalric F, et al. RNA binding fragments from nucleolin contain the ribonucleoprotein consensus sequence. J Biol Chem. 1987;262(23):10922–5. Epub 1987/08/15.PubMedGoogle Scholar
- Escande-Geraud ML, Azum MC, Tichadou JL, Gas N. Correlation between rDNA transcription and distribution of a 100 kD nucleolar protein in CHO cells. Exp Cell Res. 1985;161(2):353–63. Epub 1985/12/01.View ArticlePubMedGoogle Scholar
- Borer RA, Lehner CF, Eppenberger HM, Nigg EA. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell. 1989;56(3):379–90. Epub 1989/02/10.View ArticlePubMedGoogle Scholar
- Guttman M, Mies C, Dudycz-Sulicz K, Diskin SJ, Baldwin DA, Stoeckert Jr CJ, et al. Assessing the significance of conserved genomic aberrations using high resolution genomic microarrays. PLoS Genet. 2007;3(8):e143. Epub 2007/08/29.View ArticlePubMedPubMed CentralGoogle Scholar
- Christian S, Pilch J, Akerman ME, Porkka K, Laakkonen P, Ruoslahti E. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol. 2003;163(4):871–8. Epub 2003/11/26.View ArticlePubMedPubMed CentralGoogle Scholar
- Bose S, Basu M, Banerjee AK. Role of nucleolin in human parainfluenza virus type 3 infection of human lung epithelial cells. J Virol. 2004;78(15):8146–58. Epub 2004/07/16.View ArticlePubMedPubMed CentralGoogle Scholar
- Sinclair JF, O’Brien AD. Cell surface-localized nucleolin is a eukaryotic receptor for the adhesin intimin-gamma of enterohemorrhagic Escherichia coli O157:H7. J Biol Chem. 2002;277(4):2876–85. Epub 2001/11/13.View ArticlePubMedGoogle Scholar
- Semenkovich CF, Ostlund Jr RE, Olson MO, Yang JW. A protein partially expressed on the surface of HepG2 cells that binds lipoproteins specifically is nucleolin. Biochemistry. 1990;29(41):9708–13. Epub 1990/10/16.View ArticlePubMedGoogle Scholar
- Janakiram M, Chinai J, Fineberg S, Fiser A, Montagna C, Medaverepu R, et al. Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. Clin Cancer Res. 2014. Epub 2015/01/01.Google Scholar
- Jirawatnotai S, Sharma S, Michowski W, Suktitipat B, Geng Y, Quackenbush J, et al. The cyclin D1-CDK4 oncogenic interactome enables identification of potential novel oncogenes and clinical prognosis. Cell Cycle. 2014;13(18):2889–900. Epub 2014/12/09.View ArticlePubMedPubMed CentralGoogle Scholar
- Nielsen KV, Ejlertsen B, Moller S, Jorgensen JT, Knoop A, Knudsen H, et al. The value of TOP2A gene copy number variation as a biomarker in breast cancer: update of DBCG trial 89D. Acta Oncol. 2008;47(4):725–34. Epub 2008/05/10.View ArticlePubMedGoogle Scholar
- Thompson PA, Brewster AM, Kim-Anh D, Baladandayuthapani V, Broom BM, Edgerton ME, et al. Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer. PLoS One. 2011;6(8):e23543. Epub 2011/08/23.View ArticlePubMedPubMed CentralGoogle Scholar
- Sternlicht MD, Dunning AM, Moore DH, Pharoah PD, Ginzinger DG, Chin K, et al. Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2107–14. Epub 2006/11/23.View ArticlePubMedPubMed CentralGoogle Scholar
- Yamamoto S, Yamamoto-Ibusuki M, Yamamoto Y, Fujiwara S, Iwase H. A comprehensive analysis of Aurora A; transcript levels are the most reliable in association with proliferation and prognosis in breast cancer. BMC Cancer. 2013;13:217. Epub 2013/05/01.View ArticlePubMedPubMed CentralGoogle Scholar
- Park HS, Jang MH, Kim EJ, Kim HJ, Lee HJ, Kim YJ, et al. High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Mod Pathol. 2014;27(9):1212–22. Epub 2014/01/11.View ArticlePubMedGoogle Scholar
- Magbanua MJ, Melisko M, Roy R, Sosa EV, Hauranieh L, Kablanian A, et al. Molecular profiling of tumor cells in cerebrospinal fluid and matched primary tumors from metastatic breast cancer patients with leptomeningeal carcinomatosis. Cancer Res. 2013;73(23):7134–43. Epub 2013/10/22.View ArticlePubMedGoogle Scholar
- White TE, Saltzman RA, Di Sant’Agnese PA, Keng PC, Sutherland RM, Miller RK. Human choriocarcinoma (JAr) cells grown as multicellular spheroids. Placenta. 1988;9(6):583–98. Epub 1988/11/01.View ArticlePubMedGoogle Scholar
- Sharma-Walia N, Paul AG, Bottero V, Sadagopan S, Veettil MV, Kerur N, et al. Kaposi’s sarcoma associated herpes virus (KSHV) induced COX-2: a key factor in latency, inflammation, angiogenesis, cell survival and invasion. PLoS Pathog. 2010;6(2):e1000777.View ArticlePubMedPubMed CentralGoogle Scholar